Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

783 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.
Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA. Serrano C, et al. J Clin Oncol. 2015 Aug 1;33(22):e93-6. doi: 10.1200/JCO.2013.48.7488. Epub 2014 Mar 31. J Clin Oncol. 2015. PMID: 24687822 Free PMC article. No abstract available.
The rs17084733 variant in the KIT 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility.
Ravegnini G, Serrano C, Simeon V, Sammarini G, Nannini M, Roversi E, Urbini M, Ferrè F, Ricci R, Tarantino G, Pantaleo MA, Hrelia P, Angelini S. Ravegnini G, et al. Among authors: serrano c. Epigenetics. 2019 Jun;14(6):545-557. doi: 10.1080/15592294.2019.1595997. Epub 2019 Apr 13. Epigenetics. 2019. PMID: 30983504 Free PMC article.
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
García-Valverde A, Rosell J, Serna G, Valverde C, Carles J, Nuciforo P, Fletcher JA, Arribas J, Politz O, Serrano C. García-Valverde A, et al. Among authors: serrano c. Mol Cancer Ther. 2020 Jun;19(6):1289-1297. doi: 10.1158/1535-7163.MCT-19-1069. Epub 2020 May 5. Mol Cancer Ther. 2020. PMID: 32371592
Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Lostes-Bardaji MJ, et al. Among authors: serrano c. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498. doi: 10.1177/1758835920986498. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33473249 Free PMC article. Review.
Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF, García-Valverde A, Gomez-Peregrina D, Serrano C. Pilco-Janeta DF, et al. Among authors: serrano c. Expert Opin Emerg Drugs. 2021 Mar;26(1):53-62. doi: 10.1080/14728214.2021.1896704. Epub 2021 Mar 10. Expert Opin Emerg Drugs. 2021. PMID: 33645383 Review.
Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic options.
Ravegnini G, Fosso B, Ricci R, Gorini F, Turroni S, Serrano C, Pilco-Janeta DF, Zhang Q, Zanotti F, De Robertis M, Nannini M, Pantaleo MA, Hrelia P, Angelini S. Ravegnini G, et al. Among authors: serrano c. Cancer Sci. 2022 Aug;113(8):2590-2599. doi: 10.1111/cas.15441. Epub 2022 Jun 21. Cancer Sci. 2022. PMID: 35633186 Free PMC article.
783 results